These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 38163846)
41. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Guillot TS; Miller GW Mol Neurobiol; 2009 Apr; 39(2):149-70. PubMed ID: 19259829 [TBL] [Abstract][Full Text] [Related]
42. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones. Rehavi M; Goldin M; Roz N; Weizman A Brain Res Mol Brain Res; 1998 Jun; 57(1):31-7. PubMed ID: 9630494 [TBL] [Abstract][Full Text] [Related]
43. 9-Cyclopropylmethoxy-dihydrotetrabenazine and its stereoisomers as vesicular monoamine transporter-2 inhibitors. Wang W; Lin S; Du G; Bai X; Lu J; Ye L; Wang H; Zhang R; Tian J Future Med Chem; 2022 Jul; 14(13):991-1003. PubMed ID: 35638444 [No Abstract] [Full Text] [Related]
44. High-efficiency expression and characterization of the synaptic-vesicle monoamine transporter from baculovirus-infected insect cells. Sievert MK; Thiriot DS; Edwards RH; Ruoho AE Biochem J; 1998 Mar; 330 ( Pt 2)(Pt 2):959-66. PubMed ID: 9480916 [TBL] [Abstract][Full Text] [Related]
53. Vesicular monoamine transporter 2: role as a novel target for drug development. Zheng G; Dwoskin LP; Crooks PA AAPS J; 2006 Nov; 8(4):E682-92. PubMed ID: 17233532 [TBL] [Abstract][Full Text] [Related]
54. Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration. Alter SP; Stout KA; Lohr KM; Taylor TN; Shepherd KR; Wang M; Guillot TS; Miller GW Exp Neurol; 2016 Jan; 275 Pt 1(Pt 1):17-24. PubMed ID: 26428905 [TBL] [Abstract][Full Text] [Related]
55. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. Henry JP; Botton D; Sagne C; Isambert MF; Desnos C; Blanchard V; Raisman-Vozari R; Krejci E; Massoulie J; Gasnier B J Exp Biol; 1994 Nov; 196():251-62. PubMed ID: 7823026 [TBL] [Abstract][Full Text] [Related]
56. Structural insights into vesicular monoamine storage and drug interactions. Ye J; Chen H; Wang K; Wang Y; Ammerman A; Awasthi S; Xu J; Liu B; Li W Nature; 2024 May; 629(8010):235-243. PubMed ID: 38499039 [TBL] [Abstract][Full Text] [Related]
57. Harnessing the trophic and modulatory potential of statins in a dopaminergic cell line. Schmitt M; Dehay B; Bezard E; Garcia-Ladona FJ Synapse; 2016 Mar; 70(3):71-86. PubMed ID: 26695835 [TBL] [Abstract][Full Text] [Related]
58. Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Tong J; Wilson AA; Boileau I; Houle S; Kish SJ Synapse; 2008 Nov; 62(11):873-6. PubMed ID: 18720517 [TBL] [Abstract][Full Text] [Related]
59. VMAT2 identified as a regulator of late-stage β-cell differentiation. Sakano D; Shiraki N; Kikawa K; Yamazoe T; Kataoka M; Umeda K; Araki K; Mao D; Matsumoto S; Nakagata N; Andersson O; Stainier D; Endo F; Kume K; Uesugi M; Kume S Nat Chem Biol; 2014 Feb; 10(2):141-8. PubMed ID: 24316738 [TBL] [Abstract][Full Text] [Related]
60. Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine. Lizarraga LE; Cholanians AB; Phan AV; Herndon JM; Lau SS; Monks TJ Toxicol Sci; 2015 Jan; 143(1):209-19. PubMed ID: 25370842 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]